BioSpace News Archive

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), today announced that the Company is partnering with the American Liver Foundation (ALF) in an educational campaign about chronic liver cirrhosis and its complications and to raise awareness among potential patients and healthcare providers about the Company’s Phase 2b Study of BIV201 (continuous infusion terlipressin).

Global Blood Therapeutics, Inc. announced that on December 1, 2021, the compensation committee of GBT’s board of directors granted 24 new employees restricted stock units for an aggregate of 80,270 shares of the company’s common stock.

Aligos Therapeutics, Inc. today announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 (NCT05090111).

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, issued the following statement to stockholders.

Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of its neutralizing antibody candidate, ABP 310’s ability to neutralize the emerging SARS-CoV-2 Omicron variant.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has obtained the first set of positive data showing anti-depressant properties of its lead compound, 2-bromo-LSD (“TD-0148A”) in animal depression models, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University’s (Carleton) Department of Neuroscience.

Clover Biopharmaceuticals, Ltd. and Ascentage Pharma announced that they have entered into a clinical collaboration to evaluate Clover’s SCB-313, a recombinant human TRAIL-Trimer fusion protein and Ascentage Pharma’s APG-1387, a second mitochondria-derived activator of caspase -mimetic/inhibitor of apoptosis proteins antagonist, in a Phase 1b/2 clinical trial for advanced peritoneal carcinomatosis.

XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced that James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, has initiated research coverage on XORTX.

Heron Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication.

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021.